Literature DB >> 12417228

Target and non-target ERP disturbances in first episode vs. chronic schizophrenia.

K J Brown1, C J Gonsalvez, A W F Harris, L M Williams, E Gordon.   

Abstract

OBJECTIVES: Event-related potential (ERP) abnormalities to target stimuli are reliably found in schizophrenia. However, as people with schizophrenia are thought to have difficulty discerning the relevance of incoming sensory stimuli it is also important to examine ERPs to non-targets. To differentiate between potential trait markers of the disease and deficits that might be associated with the consequence of illness chronicity, this study investigated ERPs to both target and non-target stimuli in groups of people with either first episode or chronic schizophrenia (CSz).
METHODS: Using an auditory oddball paradigm, ERPs to target, non-target before target (Nt before) and non-target after target (Nt after) stimuli were analysed for 40 patients with CSz, 40 patients with first episode schizophrenia (FESz) and two groups of normal controls matched for age and sex with their patient counterparts.
RESULTS: The FESz group showed the same pattern of amplitude disturbance as the CSz group to both targets (reduced N100, N200, P300 and increased P200) and non-targets (reduced N100) compared to controls. Both CSz and FESz groups also failed to show the changes to the P200-N200 component between targets and non-target stimuli that was exhibited by controls (smaller earlier P200 to targets vs. increased delayed P200 to non-targets) or the reduction in N100 amplitude of ERPs to the Nt after stimuli compared with ERPs to the Nt before stimuli. Previous literature has focussed on the sensitivity of P300 deficits in classifying persons into schizophrenia and non-schizophrenia groups. This study demonstrated improved accuracy in the classification of patients with schizophrenia from controls using discriminant analysis of target and non-target N100 and P200 components.
CONCLUSIONS: The results suggest that ERP disturbances are evident at the time of first referral to mental health services and may be a potential trait (rather than secondary effect) of the illness. It is important to include both target and non-target stimuli processing, and their interrelationship in future research.

Entities:  

Mesh:

Year:  2002        PMID: 12417228     DOI: 10.1016/s1388-2457(02)00290-0

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  16 in total

1.  Neurophysiological characteristics of cognitive functions in patients with first episodes of endogenous psychosis.

Authors:  I S Lebedeva; V G Kaleda; A N Barkhatova
Journal:  Neurosci Behav Physiol       Date:  2008-03

Review 2.  The development of the N1 and N2 components in auditory oddball paradigms: a systematic review with narrative analysis and suggested normative values.

Authors:  David Tomé; Fernando Barbosa; Kamila Nowak; João Marques-Teixeira
Journal:  J Neural Transm (Vienna)       Date:  2014-06-25       Impact factor: 3.575

3.  A longitudinal study of event related potentials and correlations with psychosocial functioning and clinical features in first episode psychosis patients.

Authors:  Caitlin K Monaghan; Sophie Brickman; Polly Huynh; Dost Öngür; Mei-Hua Hall
Journal:  Int J Psychophysiol       Date:  2019-05-17       Impact factor: 2.997

4.  Auditory and Visual Oddball Stimulus Processing Deficits in Schizophrenia and the Psychosis Risk Syndrome: Forecasting Psychosis Risk With P300.

Authors:  Holly K Hamilton; Scott W Woods; Brian J Roach; Katiah Llerena; Thomas H McGlashan; Vinod H Srihari; Judith M Ford; Daniel H Mathalon
Journal:  Schizophr Bull       Date:  2019-09-11       Impact factor: 9.306

5.  The N1 auditory evoked potential component as an endophenotype for schizophrenia: high-density electrical mapping in clinically unaffected first-degree relatives, first-episode, and chronic schizophrenia patients.

Authors:  John J Foxe; Sherlyn Yeap; Adam C Snyder; Simon P Kelly; Jogin H Thakore; Sophie Molholm
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-12-14       Impact factor: 5.270

6.  Reductions in the N1 and P2 auditory event-related potentials in first-hospitalized and chronic schizophrenia.

Authors:  Dean F Salisbury; K C Collins; Robert W McCarley
Journal:  Schizophr Bull       Date:  2009-03-12       Impact factor: 9.306

7.  Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands.

Authors:  Bruce I Turetsky; Tiffany A Greenwood; Ann Olincy; Allen D Radant; David L Braff; Kristin S Cadenhead; Dorcas J Dobie; Robert Freedman; Michael F Green; Raquel E Gur; Ruben C Gur; Gregory A Light; James Mintz; Keith H Nuechterlein; Nicholas J Schork; Larry J Seidman; Larry J Siever; Jeremy M Silverman; William S Stone; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Monica E Calkins
Journal:  Biol Psychiatry       Date:  2008-08-13       Impact factor: 13.382

8.  An auditory processing abnormality specific to liability for schizophrenia.

Authors:  Rachel B Force; Noah C Venables; Scott R Sponheim
Journal:  Schizophr Res       Date:  2008-06-20       Impact factor: 4.939

9.  Early auditory processing evoked potentials (N100) show a continuum of blunting from clinical high risk to psychosis in a pediatric sample.

Authors:  Joseph Gonzalez-Heydrich; Michelle Bosquet Enlow; Eugene D'Angelo; Larry J Seidman; Sarah Gumlak; April Kim; Kristen A Woodberry; Ashley Rober; Sahil Tembulkar; Kelsey Graber; Kyle O'Donnell; Hesham M Hamoda; Kara Kimball; Alexander Rotenberg; Lindsay M Oberman; Alvaro Pascual-Leone; Matcheri S Keshavan; Frank H Duffy
Journal:  Schizophr Res       Date:  2015-11-06       Impact factor: 4.939

10.  Functional abnormalities in the cortical processing of sound complexity and musical consonance in schizophrenia: evidence from an evoked potential study.

Authors:  Kuan-Yi Wu; Ching-Wen Chao; Ching-I Hung; Wei-Hong Chen; Yung-Ting Chen; Sheng-Fu Liang
Journal:  BMC Psychiatry       Date:  2013-05-30       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.